New Customers Get 10% Off – Use Code: LUX10

Metabolic Peptide

GLP-2 TZ

5.0 Reviews

GLP-2Peptides

A GLP-related research peptide label (TZ), studied for its role in metabolic regulation, glucose control, and energy balance pathways in preclinical models. Premium Research Compound.

Original price was: $139.99.Current price is: $125.99.

2 Day FAST Shipping

99%+ Purity Tests

Ships from USA

USA Lab Tested

We accept :

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

How GLP-2 TZ Works

The Science, Simplified

Metabolic Peptide

Tirzepatide is a first-in-class dual agonist that targets both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.
Key insight: While traditional peptides target only the GLP-1 pathway, the addition of the GIP component significantly enhances the body’s metabolic response. In research models, GIP acts synergistically with GLP-1 to improve insulin secretion and sensitivity while simultaneously reducing systemic inflammation.
GE
Primary

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

COL
Strongest

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Cu²⁺
Supportive

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Metabolic Reprogramming

Beyond blood sugar, Tirzepatide influences how the body stores and utilizes energy.

Key insight: Clinical trials, such as the SURPASS and SURMOUNT series, demonstrated that this dual-action approach leads to profound reductions in body weight—often exceeding 20% in long-term studies. It effectively “reprograms” the metabolic rate by signaling the brain to reduce adiposity and improving the efficiency of glucose disposal in skeletal muscle.

Hepatoprotective & Cardiovascular Benefits

Research is increasingly focused on the secondary benefits of Tirzepatide regarding organ health.

Key insight: Studies show a marked reduction in liver fat and a decrease in pro-inflammatory markers. It has been observed to improve lipid profiles, specifically lowering LDL cholesterol and triglycerides, making it a primary subject for research into cardiovascular risk reduction and non-alcoholic fatty liver disease (NAFLD).

Wrinkle Reduction Comparison

Safety Profile from Research

What clinical studies report

Tirzepatide is widely researched and has a well-documented safety profile, though its high potency requires a structured titration approach.

🧿 Common Digestive Issues

18%

Nausea

mild

17%

Diarrhea

mild

10%

Abdominal Pain

mild

Safety Advantage

Non-Suppressive Elevation

  • Low Hypoglycemia Risk: Because Tirzepatide stimulates insulin release in a glucose-dependent manner, it rarely causes dangerously low blood sugar when researched as a standalone agent.
  • Stable Half-Life: It possesses a half-life of approximately 5 days, making a once-weekly administration protocol ideal for maintaining consistent steady-state levels in a laboratory setting.
  • Renal Safety: Emerging research suggests Tirzepatide may have protective effects on kidney function, particularly in subjects with pre-existing metabolic challenges.

📊 Discontinuation Rates

🚫 Trial Exclusions

⚡ Regulatory Status

💡 Researcher Notes

Compound Information

Technical specifications for this 39aa dual agonist

🔬 Molecular Profile

What Is GLP-2 TZ?

Full Name

Tirzepatide (GLP-2 TZ)

Peptide Type

GIP / GLP-1 Dual Agonist

Sequence

39-Amino Acid Linear Peptide

Molecular Weight

4813.45 g/mol

Formula

C225H348N48O68

🧊 Storage Requirements

Stability Information

Lyophilized (powder)

Store at -20°C

(Stable for up to 2 years).

Reconstituted

Store at 2-8°C

use within 21-28 days.

Sensitivity

Keep desiccated and away from light.

📋Research Status

Development History Observation

Classification

First-in-class Dual Agonist

Primary Goal

Glycemic Control / Obesity Research

US Status

FDA Approved (Mounjaro/Zepbound)

WADA Status

Banned (Section S2)

Frequently Asked Questions

Common questions about GLP-2 TZ

In head-to-head research (such as the SURPASS-2 trial), Tirzepatide demonstrated superior results in both HbA1c reduction and weight loss compared to Semaglutide. This is attributed to its "dual" agonist nature, which hits two hormonal pathways instead of just one.
While technically a GLP-1/GIP agonist, some catalogs use "GLP-2" or similar naming conventions to differentiate specialized blends or versions of Tirzepatide (TZ). However, the primary biological mechanism remains the dual activation of the incretin pathways.
A 30mg Tirzepatide vial offers significant research flexibility. For a subject on a standard 5mg weekly protocol, a single 30mg vial provides a 6-week supply, allowing for stable, long-term observation of metabolic changes.
Researchers frequently report a significant reduction in "food noise" or obsessive thoughts about eating. This is due to the peptide's action on the satiety centers of the brain, making it an excellent subject for behavioral and appetite-regulation studies.
Clinical trials lasting up to 72 weeks have shown that Tirzepatide remains effective and generally safe, provided that the dose is titrated correctly to manage gastrointestinal side effects.

Sources & References

Peer-reviewed research

  • Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

My Account
Follow Us
Linkedin X-twitter Icon-instagram-1 Facebook-square